A Simpler Step Toward Alzheimer’s Diagnosis

Early detection is key in managing cognitive decline, and the FDA’s latest approval could make that process far easier. Blood-based testing may soon replace invasive or costly procedures, improving access to care.

This October 2025 study by Fujirebio Diagnostics, published on US Food & Drug, reports that the FDA has approved Roche and Eli Lilly’s Elecsys blood test for Alzheimer’s. The test measures the protein pTau181 in adults 55 and older showing cognitive symptoms and achieved a 97.9% accuracy rate in ruling out Alzheimer’s.

Learn More: https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease